US FDA expands Sanofi's Menactra for use in toddlers, infants as young as 9 months
This article was originally published in Scrip
Executive Summary
The US FDA expanded the license for Sanofi Pasteur's meningococcal conjugate vaccine, Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) to include a two-dose schedule for infants and toddlers as young as nine months, making it the first time the vaccine is available in the US for children in that age group.